One of the major challenges in treating Alzheimer’s and other brain-related diseases is navigating the complex defenses the brain has established. However, a recent study offers a promising new approach to this issue.
The brain’s primary line of defense is the blood-brain barrier (BBB). This biological checkpoint selectively allows essential molecules to enter while keeping out potentially harmful substances. To the brain, many medical treatments might fall into that latter category.
This new research, conducted by a team at Oregon State University (OSU), has demonstrated that specially designed nanoparticles—just a fraction of a millimeter in size—can penetrate the BBB and deliver therapeutic agents to immune cells in targeted brain regions.
“Our research marks a significant breakthrough,” says Oleh Taratula, a pharmaceutics professor at OSU.
What’s particularly clever about these nanoparticles is that they are loaded with specially selected peptides—short chains of proteins—designed to unlock the BBB’s “gates” and identify immune cells known as microglia.
Overactive microglia can lead to harmful inflammation in various neurological diseases, which is why the researchers aimed to target these cells. Successfully delivering treatments across the BBB and directly to microglia feels like a major win.
In experiments with mice, the researchers demonstrated the potential of their method in addressing a condition called cachexia, which often occurs due to various diseases, including certain cancers.
Cachexia can lead to severe weight loss in cancer patients, regardless of their dietary efforts, and is responsible for up to 30 percent of cancer-related deaths. The brain’s hypothalamus, known for housing numerous microglia, plays a significant role in this process.
“Hypothalamic inflammation is crucial in disrupting the appetite and metabolism of these patients,” Taratula notes. “As cachexia progresses, it severely affects quality of life, treatment tolerance, and overall survival.”
Mice treated with the nanoparticle delivery system showed a significant improvement in cachexia symptoms. Specifically, they experienced 50 percent less muscle loss compared to those not receiving the treatment.
While the study did not focus on Alzheimer’s directly, the technique might be applicable to a range of neurological conditions characterized by an overactive immune response, such as dementia.
The origins and progression of Alzheimer’s remain somewhat uncertain, but research suggests that microglia may not be effectively protecting the brain and could actually contribute to disease progression.
“The ability of this nanoplatform to deliver drugs across the BBB and target microglia opens new avenues for treating neurological conditions marked by brain inflammation, including Alzheimer’s and multiple sclerosis,” Taratula adds.
The findings have been published in Advanced Healthcare Materials.
